Atlas Trials

A Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of Briquilimab in Participants With Allergic Asthma

Clinical trial NCT06592768 · TERMINATED

Trial details

NCT number
NCT06592768
Sponsor
Jasper Therapeutics, Inc.
Status
TERMINATED
Phase
Phase 1
Study type
INTERVENTIONAL
Allergic Asthma
Start date
2024-11-26
Primary completion
2025-08-11
Enrollment
17

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.